ANABOLICRX

The education library

Winstrol Depot and stanozolol: medical history, evidence and risks

← All education profiles

Educational evidence summary, not personal medical advice. AI-assisted research and editorial preparation by AnabolicRX. Sources checked 23 October 2026. No independent clinical review completed. Current Canadian product authorization is not established by this article.

Identity and the importance of formulation

Stanozolol is a synthetic anabolic-androgenic steroid. Winstrol is a name associated with the drug, while this library's reference entry is titled Winstrol Depot. A profile about a molecule must still distinguish the formulation actually studied. Much of the historical human literature reviewed here concerns oral treatment, and it cannot establish equivalent benefits, exposure or safety for an injectable product.

Stanozolol's chemical structure includes a 17-alpha modification. More importantly for readers, human studies show effects beyond muscle: on reproductive hormones, circulating lipoproteins and liver-related outcomes. Calling a substance “anabolic” does not confine its activity to the tissue someone hopes to change. Human endocrine study

Historical medical benefit: hereditary angioedema

Hereditary angioedema (HAE) is a specific medical disorder, not a general description of everyday swelling. Historical stanozolol research investigated prevention of its attacks. In a 1981 study, 27 patients with biochemically confirmed HAE were followed over two years. The authors reported control of symptom frequency and intensity, alongside improvement in complement measurements that did not fully normalize. Adverse effects included menstrual changes and virilization in four women and elevated creatine phosphokinase in five men. This is evidence of a clinical benefit in a defined illness, with identifiable harms. Sheffer and colleagues, 1981

A 2007 follow-up assessed 21 patients who had continued long-term therapy. Ten reported treatment-related symptoms, including hair growth, weight gain, menstrual or postmenopausal bleeding, acne and mood changes. Five had reduced HDL cholesterol. No persistent liver-enzyme abnormalities were reported, although liver ultrasound was performed in only eight. The experience is valuable, but a small cohort of long-term continuing patients is vulnerable to survivor selection: people who stopped earlier may differ from those who remained. It does not establish safety for unrelated populations or nonmedical exposure. Sloane and colleagues, 2007

These studies explain why stanozolol had a medical role. They do not mean it should be someone's first choice today.

How current Canadian guidance changes the picture

The International/Canadian HAE guideline published in January 2026 does not recommend attenuated androgens as first-line long-term prevention. It allows that they may remain relevant for selected patients who previously benefited or face access barriers to preferred therapies. It also states that attenuated androgens should not treat acute attacks. Historical prevention research must not be mistaken for emergency-treatment advice. Betschel and colleagues, 2026

This illustrates an important principle in medical history: a treatment can have demonstrated benefit while its place in care changes as other options become available. An educational profile should preserve both facts.

Lipids: stronger evidence than a reputation for being “mild”

A 1989 crossover study in 11 male weightlifters compared oral stanozolol with injected testosterone enanthate. During the stanozolol period, HDL cholesterol fell by 33% and LDL cholesterol rose by 29%. These were blood measurements, not measured rates of heart attacks. The comparison also changed both the drug and route, so it cannot isolate route alone or tell us the exact lipid effect of injected stanozolol. Thompson and colleagues, 1989

A separate prospective study in ten postmenopausal women with osteoporosis found that total cholesterol could remain stable while HDL fell and LDL rose. This matters when reading a health claim based on a single number: an unchanged total does not mean every component is unchanged. The study was small and short, so its percentages are observations in that group rather than forecasts for an individual. Lipoprotein study, 1982

In a randomized study of 44 people with lipodermatosclerosis and venous ulcers, 21 received oral stanozolol alongside compression and 23 received the comparison treatment. Most stanozolol recipients developed lower HDL without symptoms, and measurements returned to baseline after treatment stopped. Feeling well therefore did not exclude biochemical effects. The abstract's liver-enzyme attribution and lipid units require checking against the full report, so those numerical details are not reproduced here. Carson and colleagues, 2015

Hormones and interpreting laboratory changes

A study in nine healthy men found a substantial fall in testosterone during a short oral exposure, accompanied by changes in luteinizing hormone and binding proteins. Total thyroid hormone values also fell while free thyroxine and thyroid-stimulating hormone did not change. The distinction between total and free concentrations is important: a change in a binding protein can alter a reported total without proving the same change in active hormone availability. The findings do not establish a personal recovery time or a safe exposure pattern. Small and colleagues, 1984

This research directly contradicts the assumption that an anabolic drug necessarily supports normal endogenous hormone production. Reproductive outcomes and hormone concentrations are related, but a small hormone study cannot quantify future fertility for an individual.

Liver injury can occur with injectable exposure

A published case described severe cholestasis after intramuscular stanozolol exposure in a young man. Bilirubin was markedly elevated despite comparatively modest liver-enzyme changes, and recovery took months. One case does not establish incidence, but it is sufficient to challenge the absolute claim that an injectable formulation cannot injure the liver. Case report, 2015

A 2025 report from the Latin American drug-induced liver injury registry prospectively evaluated 18 affected men. Jaundice and itching were prominent, and bilirubin could be markedly elevated while gamma-glutamyl transferase was normal or only slightly increased. This is a selected injury cohort, not a sample of everyone exposed; it describes a clinical pattern rather than the probability of developing it. Nunes and colleagues, 2025

Two additional reported cases linked severe cholestatic jaundice with bile-cast kidney injury, supported by kidney biopsies. These cases demonstrate that severe illness can involve more than the liver. They cannot establish that every kidney problem after steroid exposure has the same mechanism. Bile-cast nephropathy report

Other risks, interactions and populations needing caution

The 2026 HAE guideline describes androgen-associated virilization, potentially irreversible voice changes, menstrual effects, mood disturbances, liver toxicity and lipid changes. It identifies pregnancy, lactation, prepubertal children, androgen-dependent malignancy and hepatitis as contraindication contexts for androgen therapy. It also warns of medication interactions. A compound-specific interaction review remains unfinished; this review should not be used to judge whether a particular combination of medicines is safe. International/Canadian guideline

The positive historical HAE experience cannot erase these cautions. Conversely, adverse-event case reports should be described accurately without presenting selected severe cases as the experience of every patient.

Canadian status and veterinary records

The official Canadian record retrieved for Winstrol-V tablets, DIN 01913360, is a veterinary product for cats and dogs, listed as cancelled post market in July 2004. It is not a human-product approval and does not establish the status of Winstrol Depot. Health Canada product record

Current human-product authorization and a Canadian monograph remain unverified in this review. The presence of a substance or veterinary product in a regulatory database is not interchangeable with authorization for human use. No purchasing, importing or veterinary-to-human substitution guidance is provided.

Misconceptions to avoid